Brean Capital analyst Difei Yang weighed in today with her views on Horizon Pharma PLC (NASDAQ:HZNP), after the company reported its first-quarter results, posting revenue of $113.1 million, compared to consensus estimate of $104.2 million due to better-than-expected Pennsaid growth. Shares of HZNP are currently trading at $28.16, up $0.54, or 1.96%.
Yang wrote, “Despite a great beat on revenue during Q1 and meeting expectations on non-GAAP EPS, the share price of HZNP pulled back. Based on what we believe is achievable upwardly revised 2015 guidance, potential additional upside from acquisitions and Ravicti opportunity outside of the US in 2016, we reiterate our BUY rating.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Difei Yang has a total average return of 13.7% and a 65.9% success rate. Yang has a 54.7% average return when recommending HZNP, and is ranked #511 out of 3596 analysts.
All the 6 analysts polled by TipRanks rate Horizon stock a Buy. With a return potential of 28.65%, the stock’s 12-month consensus target price stands at $36.60.